Mendelian Randomization Evaluates IL-6 Inhibition Effects on Hepatocellular and Colorectal Cancer Risk
Genetic data shows tocilizumab does not cause specific cancers
Genetic modeling suggests that IL-6 inhibition does not causally increase the risk of hepatocellular or colorectal cancers in diverse popula…
New genetic modeling suggests the drug tocilizumab does not increase the risk of liver or colorectal cancers for patients.
IL-6 blockade causes early lipid increases but maintains cardiovascular neutrality in rheumatoid arthritis
New review clarifies how IL-6 blockers affect cholesterol in arthritis
This narrative review examines the impact of IL-6 inhibitors tocilizumab and sarilumab on lipid profiles and cardiovascular outcomes in pati…
Doctors are looking closer at why some rheumatoid arthritis medications cause early spikes in cholesterol levels and what that means for hea…
Tocilizumab shows early anti-inflammatory effects but no significant clinical benefit in STEMI or NSTEMI
Tocilizumab shows early signs of heart protection in heart attacks
This meta-analysis of randomized controlled trials evaluated tocilizumab for patients with STEMI and NSTEMI. While the intervention showed a…
A new review looks at how the drug tocilizumab affects patients with heart attacks, showing some early signs of reduced inflammation.
Review of ruxolitinib for systemic juvenile arthritis with macrophage activation syndrome
Two children with severe arthritis found relief using a new drug approach
This narrative review synthesizes a retrospective case series and literature search on ruxolitinib for systemic juvenile idiopathic arthriti…
Two children with severe arthritis complications found relief using a new drug approach, offering hope for those who struggle with standard …
Intravenous tocilizumab improves clinical activity in moderate-to-severe thyroid eye disease patients
Doctors spot four signs that predict which eye disease patients will heal fastest
This retrospective cohort study evaluated intravenous tocilizumab in 234 patients with moderate-to-severe thyroid eye disease at Beijing Ton…
A new study reveals four simple blood tests that tell doctors if a specific eye drug will work for you soon.
Qualitative review of tocilizumab use with bispecific antibodies in relapsed/refractory multiple myeloma
New drugs for myeloma need a safety net to work well
This qualitative interview review synthesizes perspectives from ten hematologists/oncologists regarding bispecific antibody (BsAb) use in…
New powerful drugs treat myeloma better, but patients need a safety net to handle side effects and stay on track for a long time.
Tisagenlecleucel in Korean patients with relapsed or refractory diffuse large B-cell lymphoma
New Lymphoma Therapy Helps Patients Live Longer
This retrospective cohort study of 79 Korean patients with relapsed or refractory diffuse large B-cell lymphoma evaluated tisagenlecleucel.
A new study shows a specific immune therapy can shrink tumors and extend life for lymphoma patients who have run out of options.
Retrospective review of tocilizumab, rituximab, and azathioprine in chronic relapsing inflammatory optic neuropathy
New Clue Found in Stubborn Eye Inflammation
This retrospective analysis reviews tocilizumab, rituximab, and azathioprine use in 60 patients with chronic relapsing inflammatory optic ne…
Knowing a patient's blood marker status can guide doctors to the right therapy to stop recurring eye inflammation.
Hospitalized COVID-19 patients receiving antiviral, antiretroviral, or immunosuppressive treatments showed variable outcomes
What helps hospitalized COVID-19 patients survive? A new model offers clues
This cohort study of 711 hospitalized subjects with coronavirus evaluated antiviral, antiretroviral, and immunosuppressive treatments.
When COVID-19 hits hard, doctors need better tools to predict who might get worse.
Biological DMARDs show marginal patient-reported outcome benefits over conventional therapy in early rheumatoid arthritis
Early rheumatoid arthritis patients report similar symptom relief with different treatment approaches
This open-label randomized trial in 795 newly diagnosed, DMARD-naïve RA patients compared three biological DMARDs plus methotrexate against …
In early rheumatoid arthritis, patients reported similar pain relief and quality-of-life improvements whether they started with conventional…